Biomemory Launches DNA Shield Offline Custody

Biomemory announced (Paris and Boston, 15 October 2026, as carried by Dark Reading on 16 October) the launch of DNA Shield, a managed service for sovereign data protection, and opened an Early Access Program.

What DNA Shield does

In Biomemory’s description, the customer selects and encrypts the material in scope; DNA Shield then encodes it into synthetic DNA held offline under managed custody. Recovery is a controlled process, deliberately triggered when needed, rather than routine or self-service access. The pitch is an offline layer separated from the active control plane and removed from the network-reachable attack surface for assets that must stay trustworthy over years or decades.

Initial use cases Biomemory lists:

Key custody continuity — designed to complement a certified HSM rather than replace one
Crown-jewel industrial IP
Regulated integrity records
Sovereign memory / golden records

CEO Laurent Guengant said DNA Shield is “the moment Biomemory moves from proving a science to delivering a commercial product,” and the first step on a roadmap from sovereign data protection into storage, molecular search and compute.

Vincent Franceschini, Biomemory’s VP of product management and co-chair of the DNA Data Storage Alliance, said DNA Shield is the first time the company is asking a customer to rely on the molecular platform operationally rather than as a research demonstration — getting encoding through to authorised recovery right, end to end.

Company background and roadmap

The launch follows Biomemory’s March 2026 acquisition of Catalog Technologies’ assets and Guengant’s appointment as CEO in July 2026. Biomemory says it is co-chair of the DNA Data Storage Alliance and plans to expand along a dated roadmap into storage from 2029, with molecular search and compute beyond that. The company spun out of Sorbonne University and CNRS and says it owns the full stack from molecular biology to enterprise software, with industrial production in Paris and, after the Catalog acquisition, Boston.

Biomemory also calls itself “the first company bringing Molecular IT to market” — that “first” framing is the company’s own claim. The release does not disclose pricing, capacity, read/write performance or named customers.

Resilience framing — company language

Biomemory markets DNA Shield as resilient to emergent risks such as advances in artificial intelligence and quantum computing. Present that as company framing, not as an independent security proof. What is concrete in the announcement is the offline, managed-custody model and the HSM-complement design for keys.

Why it matters

Long-lived keys and golden records are awkward in always-online cloud vaults. Encoding an encrypted blob into synthetic DNA under offline custody is a niche answer: slow by design, hard to ransomware remotely, and operationally closer to a sealed archive than a hot wallet. Whether Early Access becomes a real product line depends on recovery SLAs and costs that are not in today’s release.

For another extreme-longevity storage story (different tech), see Microsoft Project Silica / the 10,000-year hard drive.

What’s still unknown

Pricing, capacity tiers and recovery turnaround
Named Early Access customers
How DNA Shield interacts with existing HSM and key-ceremony processes in practice

What this means

DNA Shield Early Access: encrypt → encode to synthetic DNA → offline managed custody (Biomemory).
Key custody: complements a certified HSM, does not replace it.
Roadmap: storage from 2029; “first Molecular IT” is Biomemory’s claim.
No pricing, capacity or customers disclosed.